ABSTRACT
OBJECTIVE Efficacy and safety of ultra-rapid acting oral prandial insulin Tregopil (Tregopil) was compared with insulin aspart (IAsp) in patients with type-2 diabetes on stable doses of insulin glargine and metformin.
RESEARCH DESIGN AND METHODS In this open-label, active-controlled trial, patients with type-2 diabetes, with HbA1c ≥7% and ≤9% and 2-h postprandial glucose (PPG) ≥180 mg/dL were randomized (1:1:1) to Tregopil (30 mg [n=30], 45 mg [n=31]) and IAsp (n=30; dose titrated based on self-monitored blood glucose [SMBG]). Postprandial plasma glucose excursion (PPGE) and PPG were assessed from the standardized test meal (STM) and 9- point SMBG. The primary outcome measure was change from baseline (CFB) in HbA1c at week 24.
RESULTS The Tregopil (30 mg) arm showed significantly lesser 1-h PPGE (CFB) excursion after the STM versus IAsp (Estimated Treatment Difference [ETD], 95% CI, -45.33 mg/dL [-71.91, -8.75], P=0.001) and 1-h PPG trended towards a better control. The combined Tregopil group (30+45 mg) showed lower PPGE at 15 mins as compared to IAsp. Meal-wise analysis showed lower 1-h PPGE and PPG in the Tregopil groups post-breakfast. Clinically significant hypoglycemia was lower with Tregopil groups versus IAsp (rate ratio: 0.69).
CONCLUSIONS Tregopil demonstrated an ultra-fast onset and short-duration prandial insulin profile with good safety. Tregopil improved the 1-h PPG and overall PPG control compared to IAsp. A further reduction in HbA1c compared to baseline was not observed, likely as a result of variability in the control of fasting glucose level over the duration of the study.
Competing Interest Statement
H.E.L. is a scientific advisor for Biocon, Intarcia Pharmaceuticals, Metacure Ltd., and Poxel Pharmaceuticals and holds stocks in Abbott, AbbVie, Inc., General Electric, Gilead Sciences, Inc., IBM, Nestle, and Novartis AG. A.F. is a board member of Tolerion and Innoneo and a consultant at Acasti, Adocia, Biocon, Cardiora, Carthera, Casebia, Diamyd, Diasome, Dance, EnteraBio, Emperra, Fractyl, G-Medical, Immune Pharma, InsuLine Medical, Intarcia Therapeutics, Intra-Cellular Therapeutics, InClinica, Ipsen Biopharmaceuticals, Lexicon, Mars Symbioscience, Mediwound, Merck KGaA, Mediwound, Metronom, Mylan, Neovii, NuSirt Biopharma, Orgenesis, Oramed, Permeatus, ProSciento, RenovoRx, Rhythm Pharmaceuticals, Sanofi, Serpin, SkinJect, Suzhou Connect, Thermalin, ThermoFisher, Upkara, Veracyte, VeroScience, Xeris Pharmaceuticals, and Zucara. A.D.C. is a scientific advisor for Biocon, Fractyl Laboratories, Inc., Metavention, Sensulin Labs, LLC., vTV Therapeutics, and also a consultant at Abvance, Novo Nordisk Inc., Thetis Pharmaceutica LLC., and vTV Therapeutics and reports research support from Novo Nordisk, Inc., Senda Biosciences Inc., Cellular Longevity, Inc., dba Loyal, and holds stocks in Fractyl Laboratories, Inc., Metavention, Thetis Pharmaceuticals LLC., and Zafgen. S.R.J. has received Speaker/Advisory/Research Grants from Abbott, Astra, Biocon, Boehringer Ingelheim, Eli Lilly, Franco Indian, Glenmark, Lupin, Marico, MSD, Novartis, Novo Nordisk, Roche, Sanofi, Serdia and Zydus. S.N.A., S.L, J.P and A.M hold shares of Biocon Biologics Ltd. A.V is an ex-employee of Biocon.
Clinical Trial
CTRI/2017/11/010560 NCT03430856
Funding Statement
The study was funded by Biocon Limited, India.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial was approved by respective independent ethics committees/institutional review boards (details given below and in Supplementary methods: B of the manuscript) and conducted in accordance with the Declaration of Helsinki, Indian Council of Medical Research Ethical guidelines for Biomedical Research, and Good Clinical Practices. 1.Nirmal Hospital Pvt. Ltd. Ethics Committee, Ring Road, Surat-395 002, India gave ethical approval for this work. (PI: Dr Piyush Desai) 2.Institutional review Board (IRB), Christian Medical College, Vellore, India gave ethical approval for this work (PI: Dr. Nihal Thomas) 3.Institutional Ethics Committee, Eternal Heart Care Center & Research Institute, Jaipur, Rajasthan, India gave ethical approval for this work (PI: Dr. Jugal Bihari Gupta) 4.Institutional Ethics Committee, Madras Diabetes Research Foundation, 4, Conron Smith Rd, Gopalapuram, Chennai, Tamil Nadu 600086, India gave ethical approval for this work (PI: Dr. Mohan Vishwanathan) 5.Medilink Ethics Committee, Medilink Hospital, Opp. Someshwara Jain Temple, 132 ft Ring Road, Satellite, Ahmedabad, Gujarat 380015, India gave ethical approval for this work (Dr Ashwin Dhabi) 6.Human Welfare, Ethical Committee for Human Sciences and Research, Opp. Kama House, Ajmer Road, Jaipur, India gave ethical approval for this work (PI: Dr. Surendra Kumar Sharma) 7.K.R.M Hospital Ethics Committee, 3/92-93 Vijayant khand, Near Chinhut Crossing, Gomtinagar, Lucknow, Uttar Pradesh 226010, India gave ethical approval for this work (Dr Sandeep Gupta) 8.Diacon Hopsital Ethics Committee, 19th Main, 1st Block, Rajajinagar, Bengaluru, Karnataka 560010, India gave ethical approval for this work (PI: Dr. Aravind Ramchandra Sosale) 9.Life Care Hospital Institutional Review Board, , #2748/ 2152, M.L.N. Enclave, 16th E Cross, 8th Main, D Block, Next to Corporation Bank, Sahakar Nagar, Bengaluru, Karnataka 560092, India gave ethical approval for this work (PI: Dr. L. Sreenivasa Murthy) 10.Ramaiah Medical College Ethics Committee, MSRIT Post, MSR Nagar, Bengaluru, Karnataka 560054, India gave ethical approval for this work (PI: Dr. Mala Dharmalingam) 11.Institutional Ethics Committee, Deenanath Mangeshkar Hospital, Near Mhatre Bridge, Erandawne, Pune, Maharashtra 411004, India gave ethical approval for this work (PI: Dr. Vaishali Deshmukh) 12.Sushruta Hospital Ethics Committee, P. B. Road, Vidyanagar, Hubli, Dharwad, Karnataka, 580021, India gave ethical approval for this work (PI: Dr. Raghavendra Belgaonkar) 13.Supe Hospital Ethics Committee, Gharapure Ghat Road, Ashok Stambh, Panchavati, Nashik, Maharashtra 422002, India gave ethical approval for this work (PI: Dr. Pravin Supe) 14.Institutional Ethics Committee of Kovai Diabetes Speciality Centre and Hospital, 15, Vivekanand Road, Ram Nagar-641009, Coimbatore, Tamil Nadu, India gave ethical approval for this work (PI: Dr. Balamurugan Ramanathan) 15.Osmania Mediacl College Ethics Committee, Afzal Gunj, Hyderabad, Telangana 500012, India gave ethical approval for this work (PI: Dr. Rakesh Kumar Sahay) 16.Institutional Ethics Committee, M/S. King George Hopsital, Jagadamba Junction, Visakhapatnam, Andhra Pradesh 530002, India gave ethical approval for this work (PI: Dr. K A V Subramanyan) 17.Ethics Committee, S. P. Medical College & Associated Group of Hospitals, S P Medical College Rd, PBM Hospital, Bikaner, Rajasthan 334001, India gave ethical approval for this work (PI: Dr. Rajendra Agarwal) 18.Institutional Ethics Committee, Gandhi Medical College Hospital, Musheerabad, Secunderabad, Telangana 500033, India gave ethical approval for this work (PI: Dr. Vijay Reddy) 19.Institute Ethics Committee, Christian Medical College, CMC Chownk, Brown Road, Ludhiana, Punjab 141008, India gave ethical approval for this work (PI: Dr. Jubbin Jacob) 20.Ethics Committee of Bangalore Medical College and Research Institute, K.R. Road, Fort, Bengaluru, Karnataka 560002, India gave ethical approval for this work (PI: Dr. Raveendra Kodur)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos